Receive our newsletter – data, insights and analysis delivered to you
June 17, 2009

BioAlliance Submits Loramyc NDA to FDA

BioAlliance, the development partner of US company Strativa, has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA). The NDA has been submitted for Loramyc (miconazole Lauriad) 50mg mucoadhesive buccal tablets, an antifungal therapy for the treatment of

By cms admin

BioAlliance, the development partner of US company Strativa, has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA).

The NDA has been submitted for Loramyc (miconazole Lauriad) 50mg mucoadhesive buccal tablets, an antifungal therapy for the treatment of oropharyngeal candidiasis.

Loramyc (miconazole Lauriad) was approved in the EU in 2007 and is marketed in several EU territories.

If approved, Strativa is expecting to launch Loramyc in the US in the second half of 2010.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU